Literature DB >> 29788313

Defining Value of Cancer Therapeutics-A Health System Perspective.

Christine Leopold1, Jeffrey M Peppercorn2, S Yousuf Zafar3, Anita K Wagner1.   

Abstract

Because of the rising costs of cancer care and ongoing challenges in ensuring access to quality care, there is an increasing need to prioritize spending and define the benefits of therapy in proportion to costs. The term "value" has gained favor as means to define the relative utility of a medical intervention in terms of benefits, risks, and financial costs, which in turn can help clinicians, patients, and policy makers prioritize "high-value" care. While numerous value concepts have been proposed, a comprehensive discussion of value initiatives along the care continuum is missing. In this Commentary, we propose a health system taxonomy of value initiatives in cancer care to discuss what the field needs to progress.

Entities:  

Mesh:

Year:  2018        PMID: 29788313     DOI: 10.1093/jnci/djy079

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  1 in total

1.  Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions.

Authors:  Eirik Joakim Tranvåg; Øystein Ariansen Haaland; Bjarne Robberstad; Ole Frithjof Norheim
Journal:  JAMA Netw Open       Date:  2022-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.